ArticlePloS one2022

Analysis of residual disease in periocular basal cell carcinoma following hedgehog pathway inhibition: Follow up to the VISORB trial.

Shelby P Unsworth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.